Table 1.
Seropositivity Rates for NMO‐IgG and AQP4 Antibodies of the Three Methods for Patients with Different Groups of Diseases
| Disease groups | N | NMO‐IgG (+)a | IIF‐tissue (+) | IIF‐AQP4 (+) | ELISA‐AQP4 (+) |
|---|---|---|---|---|---|
| Neuromyelitis optica | 9 | 5 (55.6%) | 4 (44.4%) | 5 (55.6%) | 5 (55.6%) |
| Optic neuritis | 32 | 6 (18.8%) | 2 (6.3%) | 0 (0.0%) | 4 (12.5%) |
| Transverse myelitis | 13 | 2 (15.4%) | 1 (7.7%) | 1 (7.7%) | 2 (15.4%) |
| NMO spectrum disorders | 54 | 13 (24.1%) | 7 (13.0%) | 6 (11.1%) | 11 (20.4%) |
| Multiple sclerosis | 10 | 3 (30.0%) | 1 (10.0%) | 1 (10.0%) | 3 (30.0%) |
| (Optico‐spinal multiple sclerosis) | (2) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) |
| Other neurological diseases | 60 | 3 (5.0%) | 1 (1.7%) | 2 (3.3%) | 0 (0.0%) |
| Disease controls | 70 | 6 (8.6%) | 2 (2.9%) | 3 (4.3%) | 3 (4.3%) |
a
NMO‐IgG‐positive results from at least one assay.